Literature DB >> 30770936

[Management of immunological adverse events in patients treated with immune checkpoint inhibitors: ASCO clinical practice guideline summary].

Mechthild Krause1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30770936     DOI： 10.1007/s00066-019-01436-7

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  1 in total

1.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544
  1 in total
  2 in total

1.  Severe skin toxicity during whole-brain radiotherapy, targeted therapy, and additional drug intake including St. John's wort skin oil.

Authors:  Tanja Eichkorn; Fabian Schunn; Sebastian Regnery; Rami El Shafie; Juliane Hörner-Rieber; Sebastian Adeberg; Klaus Herfarth; Jürgen Debus; Laila König
Journal:  Strahlenther Onkol       Date:  2021-01-24       Impact factor: 3.621

2.  Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors.

Authors:  Luisa Maria Griewing; Claudia Schweizer; Philipp Schubert; Sandra Rutzner; Markus Eckstein; Benjamin Frey; Marlen Haderlein; Thomas Weissmann; Sabine Semrau; Antoniu-Oreste Gostian; Sarina K Müller; Maximilian Traxdorf; Heinrich Iro; Jian-Guo Zhou; Udo S Gaipl; Rainer Fietkau; Markus Hecht
Journal:  BMC Cancer       Date:  2021-03-24       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.